{
  "id": 13489403,
  "title": "Appian CEO Matthew Calkins sells $1.69m in company stock",
  "url": "https://urgent.news/2026/10/10/appian-ceo-matthew-calkins-sells-1-69m-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-10T18:16:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/appian-ceo-matthew-calkins-sells-169m-in-company-stock-93CH-4942204"
  },
  "original_language": "en",
  "account": null,
  "summary": "Appian CEO Matthew Calkins sold $1.69 million worth of company stock on October 7, 2026, through a pre-arranged Rule 10b5-1 trading plan, according to Investing.com. The CEO executed the sales in multiple transactions at prices ranging from $36.72 to $38.19 per share, with 32,600 shares sold at an average price of $37.32 and 12,400 shares sold at an average price of $37.97. Following these transactions, Mr. Calkins still directly holds 1,584,144 shares of Appian Corp Class A Common Stock. Despite selling a significant portion of his shares, Appian reported stronger-than-expected second-quarter results, with adjusted earnings of $0.13 per share and a 19% increase in revenue to $203.3 million. The company's performance was driven by a 23% rise in cloud subscription revenue and a 98% surge in stock price over the past six months.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock",
        "url": "https://urgent.news/2026/10/10/rapport-therapeutics-ceo-abraham-ceesay-sells-143-272-in-stock",
        "published": "2026-10-10T17:31:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}